1984 Volume 32 Issue Supplement9 Pages 197-201
The MICs of AC-1370 against 120 bacterial strains from patients sputum were compared with those of cefmetazole, cefotiam, cefoperazone and ceftizoxime by Dynatech MIC-2000 system, and the efficacy of AC-1370 in the treatment of eight patients (four patients with pneumonia, one with lung abscess, two with acute exacerbation of chronic respiratory tract infection and one with abscess of the chest wall) was evaluated.
The results of in vitro tests revealed that AC-1370 was active against Klebsiella pneumoniae (MIC50=3.13μg/ml, 20 strains) but was not so active against Staphylococcus aureus, Escherichia coli, Enterobacter cloacae, Serratia marcescens and Pseudomonas aeruginosa as all or some of the above four other antibacterial agents.
Two or three grams of AC-1370 per day were given to the patients by intravenous drip infusion, . Clinical response to the treatment with AC-1370 was good in all of seven community-acquired respiratory infections. Three strains of Haemophilus influenzae and one strain of Streptococcus pneumoniae were considered to be cousative organisms in four patients and were all eradicated. This drug was not effective against a patient with chest wall abscess combined with lung cancer. As for side effects during the treatment, eruption occurred in two cases, elevation of S-GPT values in one and eosinophilia in one. But all of theses abnormalities were slight and were normalized soon after cessation of the drug.
